Global in vitro diagnostics manufacturer Ortho Clinical Diagnostics, Raritan, NJ, in collaboration with Diazyme Laboratories Inc, Poway, Calif, now offers three new Microtip Partnership assays to their customers. With the new assays for cystatin c, glycated serum protein (GSP), and lipoprotein (a) (Lp (a)), Ortho enhances its offerings for diabetes monitoring as well as cardiac and renal testing. The Microtip Partnership program enables Ortho to validate and offer high-value esoteric testing, in step with evolving laboratory needs.
“Our Microtip Partnership assay program helps us expand our reach in delivering innovative, important new assays to our customers,” says Robert Yates, COO of Ortho. “Ortho is a leader in testing in diabetes, cardiac, and renal areas, and the three new assays we announce today further that position and commitment.”
Cystatin c is a key marker for early diagnosis of chronic kidney disease, and complements serum creatinine testing. Combining cystatin c with serum creatinine can improve the predictive accuracy for all-cause mortality and end-stage renal disease, as it is a more sensitive marker in the creatinine blind range in kidney testing.
The GSP assay enriches the company’s diabetes menu, adding to recent launches of Microtip Partnership assays for beta-hydroxybutyrate, c-peptide, and insulin. Glycemic monitoring is critical in the prevention or delay of diabetes-related complications and comorbidities.
The Lp (a) assay expands Ortho’s offering of diagnostic cardiac markers for patients who may have a genetic risk factor for premature cardiovascular disease, including risk stratification for myocardial infarction and stroke.
The assays will initially launch in Africa, Europe, the Middle East, and the United States. To learn more, visit Ortho Clinical Diagnostics.